newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra
Health

Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product’s Availability Across Strengths

Strides receives USFDA approval for Fluoxetine Tabs 60 mg

Strides receives USFDA approval for Fluoxetine Tabs 60 mg; Expanding the Product’s Availability Across Strengths

  • Fluoxetine Tabs 60 mg approval solidifies the Company’s position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules

Bangalore, India, September 16, 2024 – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Fluoxetine Tabs 60 mg, from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Fluoxetine Tablets, 60 mg, of TWi Pharmaceuticals, Inc.

With the approval of the Fluoxetine Tabs 60 mg strength, the Company is now positioned to offer a complete portfolio of Fluoxetine across Capsules and Tablets in 10 mg, 20 mg, and 60 mg strengths. Fluoxetine Capsules and Tablets have a combined market size of ~US$ 130 Mn as per IMS.

The addition of the Fluoxetine Tabs 60 mg will allow for enhanced flexibility in dosing, catering to a broader spectrum of patient needs. The Company plans to launch all three strengths in the near future. The Fluoxetine tablets will be manufactured at the company’s facility in Puducherry.

Related posts

Glentree Academy opens its third campus with cutting-edge earth lab facility in Bengaluru

Newsmantra

Charnock Hospital Launches ECMO Services and Second Cath Lab in Newtown

Newsmantra

Centre for Chronic Disease Control Awarded Prestigious ICMR Grant for Centre for Advanced Research

Newsmantra

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More